Porphyrias at a glance: Diagnosis and treatment

Internal and Emergency Medicine

Volumn 5, Issue SUPPL. 1, 2010, Pages 73-80

  Cappellini, Maria Domenica ^a   Brancaleoni, Valentina ^a   Graziadei, Giovanna ^a   Tavazzi, Dario ^a   Di Pierro, Elena ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

ALA; Heme; Porphobilinogen; Porphyrias; Porphyrins

Indexed keywords

AMINOLEVULINIC ACID; HEME; PORPHOBILINOGEN; PORPHYRIN;

ACUTE DISEASE; ARTICLE; CHRONIC DISEASE; GENETIC SCREENING; GENETICS; HUMAN; METABOLISM; PORPHYRIA;

ACUTE DISEASE; AMINOLEVULINIC ACID; CHRONIC DISEASE; GENETIC TESTING; HEME; HUMANS; PORPHOBILINOGEN; PORPHYRIAS; PORPHYRINS;

EID: 77957143219     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-010-0449-7     Document Type: Article

References (77)

1. Ventura E, Rocchi E (2001) Le Porfirie. In: Guarini G, Fiorelli G, Malliani A, Violi E, Volpe M (eds) Trattato di Medicina Interna Societa' Editrice Universo, Roma, pp 2301-2334.
2. Andersson K, Sassa A, Bishop D (2001) Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. In: Scriver C, Beaudet A, Sly W, Valle D et al (eds) The metabolic and molecular basis of inherited diseases. McGraw-Hill, New York, pp 2991-3062.
3. Lim CK, Peters TJ (1984) Urine and faecal porphyrin profiles by reversed-phase high-performance liquid chromatography in the porphyrias. Clin Chim Acta 139: 55-63.
4. Aarsand AK, Petersen PH, Sandberg S (2006) Estimation and application of biological variation of urinary delta-aminolevulinic acid and porphobilinogen in healthy individuals and in patients with acute intermittent porphyria. Clin Chem 52: 650-656.
5. Kuhnel A, Gross U, Doss MO (2000) Hereditary coproporphyria in Germany: clinical-biochemical studies in 53 patients. Clin Biochem 33: 465-473.
6. Hindmarsh JT, Oliveras L, Greenway DC (1999) Biochemical differentiation of the porphyrias. Clin Biochem 32: 609-619.
7. Hift RJ, Davidson BP, van der Hooft C et al (2004) Plasma fluorescence scanning and fecal porphyrin analysis for the diagnosis of variegate porphyria: precise determination of sensitivity and specificity with detection of protoporphyrinogen oxidase mutations as a reference standard. Clin Chem 50: 915-923.
8. Da Silva V, Simonin S, Deybach JC et al (1995) Variegate porphyria: diagnostic value of fluorometric scanning of plasma porphyrins. Clin Chim Acta 238: 163-168.
9. Puy H, Deybach JC, Lamoril J et al (1997) Molecular epidemiology and diagnosis of PBG deaminase gene defects in acute intermittent porphyria. Am J Hum Genet 60: 1373-1383.
10. Whatley SD, Puy H, Morgan RR et al (1999) Variegate porphyria in Western Europe: identification of PPOX gene mutations in 104 families, extent of allelic heterogeneity, and absence of correlation between phenotype and type of mutation. Am J Hum Genet 65: 984-994.
11. Lamoril J, Puy H, Whatley SD et al (2001) Characterization of mutations in the CPO gene in British patients demonstrates absence of genotype-phenotype correlation and identifies relationship between hereditary coproporphyria and harderoporphyria. Am J Hum Genet 68: 1130-1138.
12. Martinez di Montemuros F, Di Pierro E, Biolcati G et al (2001) Acute intermittent porphyria: heterogeneity of mutations in the hydroxymethylbilane synthase gene in Italy. Blood Cells Mol Dis 27: 961-970.
13. Di Pierro E, Ventura P, Brancaleoni V et al (2009) Clinical, biochemical and genetic characteristics of Variegate Porphyria in Italy. Cell Mol Biol (Noisy-le-grand) 55: 79-88.
14. Ventura P, Cappellini MD, Rocchi E (2009) The acute porphyrias: a diagnostic and therapeutic challenge in internal and emergency medicine. Intern Emerg Med 4(4): 297-308.
15. Meissner PN, Dailey TA, Hift RJ et al (1996) A R59 W mutation in human protoporphyrinogen oxidase results in decreased enzyme activity and is prevalent in South Africans with variegate porphyria. Nat Genet 13: 95-97.
16. Floderus Y, Shoolingin-Jordan PM, Harper P (2002) Acute intermittent porphyria in Sweden. Molecular, functional and clinical consequences of some new mutations found in the porphobilinogen deaminase gene. Clin Genet 62: 288-297.
17. Di PE, Besana V, Moriondo V et al (2006) A large deletion on chromosome 11 in acute intermittent porphyria. Blood Cells Mol Dis 37: 50-54.
18. Whatley SD, Mason NG, Woolf JR et al (2009) Diagnostic strategies for autosomal dominant acute porphyrias: retrospective analysis of 467 unrelated patients referred for mutational analysis of the HMBS, CPOX, or PPOX gene. Clin Chem 55: 1406-1414.
19. Di Pierro E, Brancaleoni V, Besana V et al (2009) Multiplex ligation-dependent probe amplification: a novel approach for genetic diagnosis of porphyria. J Hum Genet 54: 479-487.
20. Kauppinen R, Mustajoki P (1992) Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine (Baltimore) 71: 1-13.
21. Puy H, Gouya L, Deybach JC (2010) Porphyrias. Lancet 375: 924-937.
22. Anderson KE, Bloomer JR, Bonkovsky HL et al (2005) Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med 142: 439-450.
23. Mustajoki P, Nordmann Y (1993) Early administration of heme arginate for acute porphyric attacks. Arch Intern Med 153: 2004-2008.
24. Mustajoki P, Tenhunen R, Pierach C et al (1989) Heme in the treatment of porphyrias and hematological disorders. Semin Hematol 26: 1-9.
25. Bonkovsky HL, Healey JF, Lourie AN et al (1991) Intravenous heme-albumin in acute intermittent porphyria: evidence for repletion of hepatic hemoproteins and regulatory heme pools. Am J Gastroenterol 86: 1050-1056.
26. Anderson KE, Bonkovsky HL, Bloomer JR et al (2006) Reconstitution of hematin for intravenous infusion. Ann Intern Med 144: 537-538.
27. Badminton MN, Deybach JC (2006) Treatment of an acute attack of porphyria during pregnancy. Eur J Neurol 13: 668-669.
28. Pischik E, Kauppinen R (2006) Can pregnancy stop cyclical attacks of porphyria? Am J Med 119: 88-90.
29. Seth AK, Badminton MN, Mirza D et al (2007) Liver transplantation for porphyria: Who, when, and how? Liver Transpl 13: 1219-1227.
30. Doss MO, Kuhnel A, Gross U (2000) Alcohol and porphyrin metabolism. Alcohol Alcohol 35: 109-125.
31. Thunell S, Pomp E, Brun A (2007) Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias. Br J Clin Pharmacol 64: 668-679.
32. Bylesjo I, Wikberg A, Andersson C (2009) Clinical aspects of acute intermittent porphyria in northern Sweden: a population-based study. Scand J Clin Lab Invest 69: 612-618.
33. Andersson C, Lithner F (1994) Hypertension and renal disease in patients with acute intermittent porphyria. J Intern Med 236: 169-175.
34. Andant C, Puy H, Bogard C et al (2000) Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. J Hepatol 32: 933-939.
35. Laiwah AA, Mactier R, McColl KE et al (1983) Early-onset chronic renal failure as a complication of acute intermittent porphyria. Q J Med 52: 92-98.
36. Al-Karadaghi S, Hansson M, Nikonov S et al (1997) Crystal structure of ferrochelatase: the terminal enzyme in heme biosynthesis. Structure 5: 1501-1510.
37. Schneider-Yin X, Gouya L, Meier-Weinand A et al (2000) New insights into the pathogenesis of erythropoietic protoporphyria and their impact on patient care. Eur J Pediatr 159: 719-725.
38. Christiansen L, Bygum A, Jensen A et al (2000) Association between CYP1A2 polymorphism and susceptibility to porphyria cutanea tarda. Hum Genet 107: 612-614.
39. Bulaj ZJ, Phillips JD, Ajioka RS et al (2000) Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood 95: 1565-1571.
40. Cruz-Rojo J, Fontanellas A, Moran-Jimenez MJ et al (2002) Precipitating/aggravating factors of porphyria cutanea tarda in Spanish patients. Cell Mol Biol (Noisy-le-grand) 48: 845-852.
41. Lamoril J, Andant C, Gouya L et al (2002) Hemochromatosis (HFE) and transferrin receptor-1 (TFRC1) genes in sporadic porphyria cutanea tarda (sPCT). Cell Mol Biol (Noisy-le-grand) 48: 33-41.
42. Gisbert JP, Garcia-Buey L, Pajares JM et al (2003) Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol 39: 620-627.
43. Gardlo K, Selimovic D, Bolsen K et al (2003) Cytochrome p450A1 polymorphisms in a Caucasian population with porphyria cutanea tarda. Exp Dermatol 12: 843-848.
44. Albalate M, Farinas MC, Octavio JG et al (2001) Development of porphyria cutanea tarda in a hemodialysis patient after reactivation of hepatitis C virus infection. Nephron 88: 170-173.
45. Whatley SD, Ducamp S, Gouya L et al (2008) C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. Am J Hum Genet 83: 408-414.
46. Hindmarsh JT, Oliveras L, Greenway DC (1999) Plasma porphyrins in the porphyrias. Clin Chem 45: 1070-1076.
47. Elder GH (1998) Porphyria cutanea tarda. Semin Liver Dis 18: 67-75.
48. Cox TM (1997) Erythropoietic protoporphyria. J Inherit Metab Dis 20: 258-269.
49. Elder GH, Roberts AG (1995) Uroporphyrinogen decarboxylase. J Bioenerg Biomembr 27: 207-214.
50. Di Pierro E, Brancaleoni V, Besana V et al (2008) A 10376 bp deletion of FECH gene responsible for erythropoietic protoporphyria. Blood Cells Mol Dis 40: 233-236.
51. Di Pierro E, Brancaleoni V, Moriondo V et al (2007) Co-existence of two functional mutations on the same allele of the human ferrochelatase gene in erythropoietic protoporphyria. Clin Genet 71: 84-88.
52. Whatley SD, Mason NG, Holme SA et al (2007) Gene dosage analysis identifies large deletions of the FECH gene in 10% of families with erythropoietic protoporphyria. J Invest Dermatol 127: 2790-2794.
53. Minder EI, Gouya L, Schneider-Yin X et al (2002) A genotype-phenotype correlation between null-allele mutations in the ferrochelatase gene and liver complication in patients with erythropoietic protoporphyria. Cell Mol Biol (Noisy-le-grand) 48: 91-96.
54. Shady AA, Colby BR, Cunha LF et al (2002) Congenital erythropoietic porphyria: identification and expression of eight novel mutations in the uroporphyrinogen III synthase gene. Br J Haematol 117: 980-987.
55. Phillips JD, Steensma DP, Pulsipher MA et al (2007) Congenital erythropoietic porphyria due to a mutation in GATA1: the first trans-acting mutation causative for a human porphyria. Blood 109: 2618-2621.
56. Ciovacco WA, Raskind WH, Kacena MA (2008) Human phenotypes associated with GATA-1 mutations. Gene 427: 1-6.
57. Gouya L, Puy H, Lamoril J et al (1999) Inheritance in erythropoietic protoporphyria: a common wild-type ferrochelatase allelic variant with low expression accounts for clinical manifestation. Blood 93: 2105-2110.
58. Gouya L, Puy H, Robreau AM et al (2002) The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH. Nat Genet 30: 27-28.
59. Di Pierro E, Cappellini MD, Mazzucchelli R et al (2005) A point mutation affecting an SP1 binding site in the promoter of the ferrochelatase gene impairs gene transcription and causes erythropoietic protoporphyria. Exp Hematol 33: 584-591.
60. Sarkany RP (2001) The management of porphyria cutanea tarda. Clin Exp Dermatol 26: 225-232.
61. Lecha M, Herrero C, Ozalla D (2003) Diagnosis and treatment of the hepatic porphyrias. Dermatol Ther 16: 65-72.
62. Ippen H (1977) Treatment of porphyria cutanea tarda by phlebotomy. Semin Hematol 14: 253-259.
63. Badminton MN, Elder GH (2002) Management of acute and cutaneous porphyrias. Int J Clin Pract 56: 272-278.
64. Egger NG, Motamedi M, Pow-Sang M et al (1996) Accumulation of porphyrins in plasma and tissues of dogs after delta-aminolevulinic acid administration: implications for photodynamic therapy. Pharmacology 52: 362-370.
65. Valls V, Ena J, Enriquez-De-Salamanca R (1994) Low-dose oral chloroquine in patients with porphyria cutanea tarda and low-moderate iron overload. J Dermatol Sci 7: 169-175.
66. Anderson KE, Goeger DE, Carson RW et al (1990) Erythropoietin for the treatment of porphyria cutanea tarda in a patient on long-term hemodialysis. N Engl J Med 322: 315-317.
67. Peces R, de Enriquez SR, Fontanellas A et al (1994) Successful treatment of haemodialysis-related porphyria cutanea tarda with erythropoietin. Nephrol Dial Transplant 9: 433-435.
68. Minder EI, Schneider-Yin X, Steurer J et al (2009) A systematic review of treatment options for dermal photosensitivity in erythropoietic protoporphyria. Cell Mol Biol (Noisy-le-grand) 55: 84-97.
69. Harms J, Lautenschlager S, Minder CE et al (2009) An alpha-melanocyte-stimulating hormone analogue in erythropoietic protoporphyria. N Engl J Med 360: 306-307.
70. Holme SA, Whatley SD, Roberts AG et al (2009) Seasonal palmar keratoderma in erythropoietic protoporphyria indicates autosomal recessive inheritance. J Invest Dermatol 129: 599-605.
71. McGuire BM, Bonkovsky HL, Carithers RL Jr et al (2005) Liver transplantation for erythropoietic protoporphyria liver disease. Liver Transpl 11: 1590-1596.
72. Wahlin S, Srikanthan N, Hamre B et al (2008) Protection from phototoxic injury during surgery and endoscopy in erythropoietic protoporphyria. Liver Transpl 14: 1340-1346.
73. Rand EB, Bunin N, Cochran W et al (2006) Sequential liver and bone marrow transplantation for treatment of erythropoietic protoporphyria. Pediatrics 118: e1896-e1899.
74. Harada FA, Shwayder TA, Desnick RJ et al (2001) Treatment of severe congenital erythropoietic porphyria by bone marrow transplantation. J Am Acad Dermatol 45: 279-282.
75. Kontos AP, Ozog D, Bichakjian C et al (2003) Congenital erythropoietic porphyria associated with myelodysplasia presenting in a 72-year-old man: report of a case and review of the literature. Br J Dermatol 148: 160-164.
76. Shaw PH, Mancini AJ, McConnell JP et al (2001) Treatment of congenital erythropoietic porphyria in children by allogeneic stem cell transplantation: a case report and review of the literature. Bone Marrow Transplant 27: 101-105.
77. Robert-Richard E, Moreau-Gaudry F, Lalanne M et al (2008) Effective gene therapy of mice with congenital erythropoietic porphyria is facilitated by a survival advantage of corrected erythroid cells. Am J Hum Genet 82: 113-124.